USE OF REAL-WORLD EVIDENCE IN EUROPEAN MEDICINES AGENCY DECISIONS

被引：0
|
作者：
Watson, C. [1 ]
Jones, G. [1 ]
Shaw, C. [1 ]
机构：
[1] PHMR Ltd, London, England
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
P33
引用
收藏
页码：S8 / S8
页数：1
相关论文
共 50 条
  • [1] The use of real-world evidence in European medicines regulation
    Brown, Jeremy P.
    Wing, Kevin
    Evans, Stephen
    Bhaskaran, Krishnan
    Smeeth, Liam
    Douglas, Ian
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 205 - 206
  • [2] Real World Evidence: European Medicines Agency Experience
    Arlett, Peter
    JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2020, 23 : 10S - 13S
  • [3] Contribution of Real-World Evidence in European Medicines Agency's Regulatory Decision Making
    Bakker, Elisabeth
    Plueschke, Kelly
    Jonker, Carla J.
    Kurz, Xavier
    Starokozhko, Viktoriia
    Mol, Peter G. M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 (01) : 135 - 151
  • [4] Use of real-world evidence in postmarketing medicines regulation in the European Union: a systematic assessment of European Medicines Agency referrals 2013-2017
    Brown, Jeremy Philip
    Wing, Kevin
    Evans, Stephen J.
    Bhaskaran, Krishnan
    Smeeth, Liam
    Douglas, Ian J.
    BMJ OPEN, 2019, 9 (10):
  • [5] The Use of Real-World Evidence for Regulatory Decisions in China
    Xu, Jiayue
    Wu, Wenkai
    Zhang, Xia
    Ren, Yan
    Yao, Minghong
    Liu, Mei
    Zou, Kang
    Wang, Wen
    Sun, Xin
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 116 (01) : 82 - 95
  • [6] Real-World Evidence and the Regulation of Medicines
    Honig, Peter K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 (05) : 1169 - 1172
  • [7] Marketing Authorization Applications Made to the European Medicines Agency in 2018-2019: What was the Contribution of Real-World Evidence?
    Flynn, Robert
    Plueschke, Kelly
    Quinten, Chantal
    Strassmann, Valerie
    Duijnhoven, Ruben G.
    Gordillo-Maranon, Maria
    Rueckbeil, Marcia
    Cohet, Catherine
    Kurz, Xavier
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 (01) : 90 - 97
  • [8] USE OF SECONDARY REAL-WORLD DATA FROM THE UNITED STATES TO FULFILL EUROPEAN MEDICINES AGENCY POST AUTHORIZATION REQUIREMENT
    Knight, T. G.
    Plante, K.
    Ruggieri, A.
    VALUE IN HEALTH, 2024, 27 (12) : S604 - S604
  • [9] Understanding Use of Real-World Data and Real-World Evidence to Support Regulatory Decisions on Medical Product Effectiveness
    Mahendraratnam, Nirosha
    Mercon, Kerra
    Gill, Mira
    Benzing, Laura
    McClellan, Mark B.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 (01) : 150 - 154
  • [10] Real-World Evidence in EU Medicines Regulation: Enabling Use and Establishing Value
    Arlett, Peter
    Kjaer, Jesper
    Broich, Karl
    Cooke, Emer
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 (01) : 21 - 23
12345